| Original language | English (US) |
|---|---|
| Pages (from-to) | 1273-1284 |
| Number of pages | 12 |
| Journal | Diabetes care |
| Volume | 40 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2017 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Diabetes care, Vol. 40, No. 9, 01.09.2017, p. 1273-1284.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Diabetes and hypertension
T2 - A position statement by the American diabetes association
AU - De Boer, Ian H.
AU - Bangalore, Sripal
AU - Benetos, Athanase
AU - Davis, Andrew M.
AU - Michos, Erin D.
AU - Muntner, Paul
AU - Rossing, Peter
AU - Zoungas, Sophia
AU - Bakris, George
N1 - Funding Information: express our gratitude and thanks to Erika Gebel Berg of the ADA for her help in writing the manuscript drafts and coalescing information from all the authors. Funding and Duality of Interest. I.H.d.B. has been a consultant for Boehringer Ingelheim and Ironwood Pharmaceuticals, and his institution has received research equipment and supplies from Medtronic and Abbott. S.B. has received research grants from the National Heart, Lung, and Blood Institute and Abbott Vascular; has been on advisory boards for Pfizer, AstraZeneca, and The Medicines Company; and has received speaker fees from Merck, Abbott, Pfizer, and Abbott Vascular. A.B. has received honoraria from Fukuda-Denshi. E.D.M. has received an honorarium from Siemens Healthcare Diagnostics for being a blinded events adjudicator in a clinical trial unrelated to the subject of this article (i.e., it was not related to either hypertension or diabetes). P.M. has received research support and honorarium from Amgen. P.R. has been a steering committee member for A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) (AstraZeneca) and Efficacy and Safety of Finere-none in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO)/Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO) (Bayer) and has received consultancy and/or speaking fees (all honoraria to his institution) from AbbVie, Astellas, As-traZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. S.Z. has been a consultant for AstraZeneca/Bristol-Myers Squibb Australia, Janssen-Cilag, Merck Sharp & Dohme, Novo Nordisk, Sanofi Australia, and Servier International. G.B. has been a principal investigator on FIDELIO (Bayer), a steering committee member for Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) (Janssen) and Study Of Diabetic Nephropathy With Atrasentan (SONAR) (AbbVie), and a consultant for Merck, Re-lypsa, Vascular Dynamics, GlaxoSmithKline, Bayer, Janssen, and AbbVie. No other potential conflicts of interest relevant to this article were reported.
PY - 2017/9/1
Y1 - 2017/9/1
UR - http://www.scopus.com/inward/record.url?scp=85028072849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028072849&partnerID=8YFLogxK
U2 - 10.2337/dci17-0026
DO - 10.2337/dci17-0026
M3 - Article
C2 - 28830958
AN - SCOPUS:85028072849
SN - 0149-5992
VL - 40
SP - 1273
EP - 1284
JO - Diabetes care
JF - Diabetes care
IS - 9
ER -